Histone deacetylase inhibitors in lymphoma and solid malignancies

References

• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer6(1), 38–51 (2006).
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res.5(10), 981–989 (2007).
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene26(37), 5541–5552 (2007).
   PubMed Web of Science ®Google Scholar
• Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol.338(1), 17–31 (2004).
   PubMed Web of Science ®Google Scholar
• Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol.23(17), 3971–3993 (2005).
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov.5(9), 769–784 (2006).
   PubMed Web of Science ®Google Scholar
• Lund AH, Van Lohuizen M. Epigenetics and cancer. Genes Dev.18(19), 2315–2335 (2004).
   PubMed Web of Science ®Google Scholar
• Baylin SB, Ohm JE. Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer6(2), 107–116 (2006).
   PubMed Web of Science ®Google Scholar
• Rice JC, Allis CD. Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr. Opin. Cell Biol.13(3), 263–273 (2001).
   PubMed Web of Science ®Google Scholar
• Redner RL, Wang J, Liu JM. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood94(2), 417–428 (1999).
   PubMed Web of Science ®Google Scholar
• Jones LK, Saha V. Chromatin modification, leukaemia and implications for therapy. Br. J. Haematol.118(3), 714–727 (2002).
   PubMed Web of Science ®Google Scholar
• Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A. Histone acetylation and disease. Cell. Mol. Life Sci.58(5–6), 728–736 (2001).
   PubMed Web of Science ®Google Scholar
• Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol.184(1), 1–16 (2000).
   PubMed Web of Science ®Google Scholar
• Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs13(1), 1–13 (2002).
   PubMed Web of Science ®Google Scholar
• Santini V, Gozzini A, Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr. Drug Metab.8(4), 383–393 (2007).
   PubMed Web of Science ®Google Scholar
• Fenrick R, Hiebert SW. Role of histone deacetylases in acute leukemia. J. Cell. Biochem. Suppl.30–31, 194–202 (1998).
   PubMedGoogle Scholar
• Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. Eto, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl Acad. Sci. USA95(18), 10860–10865 (1998).
   PubMed Web of Science ®Google Scholar
• Lin RJ, Sternsdorf T, Tini M, Evans RM. Transcriptional regulation in acute promyelocytic leukemia. Oncogene20(49), 7204–7215 (2001).
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Bereschenko O, Niu H et al. Molecular pathogenesis of non-Hodgkin’s lymphoma: the role of Bcl-6. Leuk. Lymphoma44(Suppl. 3), S5–S12 (2003).
   PubMed Web of Science ®Google Scholar
• Marchion D, Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert. Rev. Anticancer Ther.7(4), 583–598 (2007).
   PubMed Web of Science ®Google Scholar
• Fraga MF, Ballestar E, Villar-Garea A et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet.37(4), 391–400 (2005).
   PubMed Web of Science ®Google Scholar
• Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature444(7121), 868–874 (2006).
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J. Cell. Biochem.96(2), 293–304 (2005).
   PubMed Web of Science ®Google Scholar
• Munster PN, Troso-Sandoval T, Rosen N et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res.61(23), 8492–8497 (2001).
   PubMed Web of Science ®Google Scholar
• Zhou Q, Melkoumian ZK, Lucktong A et al. Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J. Biol. Chem.275(45), 35256–35263 (2000).
   PubMed Web of Science ®Google Scholar
• Bishton M, Kenealy M, Johnstone R, Rasheed W, Prince HM. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Expert. Rev. Anticancer Ther.7(10), 1439–1449 (2007).
   PubMed Web of Science ®Google Scholar
• Vrana JA, Decker RH, Johnson CR et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene18(50), 7016–7025 (1999).
   PubMed Web of Science ®Google Scholar
• Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA97(18), 10014–10019 (2000).
   PubMed Web of Science ®Google Scholar
• Burgess AJ, Pavey S, Warrener R et al. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol. Pharmacol.60(4), 828–837 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang K, Dent SY. Histone modifying enzymes and cancer: going beyond histones. J. Cell. Biochem.96(6), 1137–1148 (2005).
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet.3(6), 415–428 (2002).
   PubMed Web of Science ®Google Scholar
• Druesne N, Pagniez A, Mayeur C et al. Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis25(7), 1227–1236 (2004).
   PubMed Web of Science ®Google Scholar
• Myzak MC, Karplus PA, Chung FL, Dashwood RH. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res.64(16), 5767–5774 (2004).
   PubMed Web of Science ®Google Scholar
• Zhu P, Martin E, Mengwasser J et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell5(5), 455–463 (2004).
   PubMed Web of Science ®Google Scholar
• Butler LM, Zhou X, Xu WS et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl Acad. Sci. USA99(18), 11700–11705 (2002).
   PubMed Web of Science ®Google Scholar
• Ruefli AA, Ausserlechner MJ, Bernhard D et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl Acad. Sci. USA98(19), 10833–10838 (2001).
   PubMed Web of Science ®Google Scholar
• Peart MJ, Tainton KM, Ruefli AA et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res.63(15), 4460–4471 (2003).
   PubMed Web of Science ®Google Scholar
• Lindemann RK, Newbold A, Whitecross KF et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc. Natl Acad. Sci. USA104(19), 8071–8076 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J. Invest. Dermatol.125(5), 1045–1052 (2005).
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Heaney ML, Schwartz L et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol.24(1), 166–173 (2006).
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood109(1), 31–39 (2007).
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol.25(21), 3109–3115 (2007).
   PubMed Web of Science ®Google Scholar
• Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol.25(1), 84–90 (2007).
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, He K et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin. Cancer Res.13(8), 2318–2322 (2007).
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Robey RW, Zhan Z et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood103(12), 4636–4643 (2004).
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Robey R, Sandor V et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood98(9), 2865–2868 (2001).
   PubMed Web of Science ®Google Scholar
• Nebozhyn M, Loboda A, Kari L et al. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood107(8), 3189–3196 (2006).
   PubMedGoogle Scholar
• Piekarz R, Frye R, Wright J et al. Update of the NCI multiinstitutional Phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma. J. Clin. Oncol.250(18 Suppl.), (2007) (Abstract 8027).
   Google Scholar
• Kim YH, Reddy S, Kim EJ et al. Romidepsin (depsipeptide) induces clinically significant responses in treatment-refractory CTCL. An International, Multicenter Study. American Society of Hematology Annual Meeting Abstracts110(11), (2007) (Abstract 123).
   Google Scholar
• Ellis L, Pan Y, Smyth G et al. The histone deacetylase inhibitor LBH589 induces responses with associated alterations in gene expression profiles in cutaneous T cell lymphoma. Clin. Cancer Res.(2008) (In press).
   Google Scholar
• Sharma S, Vogelzang NJ, Beck J et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589, a novel deacetylase (DAC) inhibitor given intravenously on a new once weekly schedule. J. Clin. Oncol.28(18 Suppl.), (2007) (Abstract 14019).
   Google Scholar
• Ryan QC, Headlee D, Acharya M et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol.23(17), 3912–3922 (2005).
   PubMed Web of Science ®Google Scholar
• Spencer A, Prince M, Deangelo DJ et al. Phase IA/II study of oral LBH589, a novel deacetylase inhibitor (DACi), administered on 2 schedules, in patients with advanced hematologic malignancies. ASH Annual Meeting Abstracts110(11), (2007 (Abstract 907).
   Google Scholar
• Georgakis GV, Yazbeck VY, Li Y, Younes A. The histone deacetylase inhibitor vorinostat (SAHA) induces apoptosis and cell-cycle arrest in Hodgkin lymphoma (HL) cell lines by altering several survival signaling pathways and synergizes with doxorubicin, gemcitabine and bortezomib. American Society of Hematology Annual Meeting Abstracts108(11), (2006) (Abstract 2260).
   Google Scholar
• Buglio D, Georgakis G, Arima K, Liu Y-J, Younes A. Vorinostat (SAHA) inhibits STAT6 phosphorylation and transcription, downregulates Bcl-xL, and induces apoptosis in Hodgkin lymphoma (HL) cell lines. American Society of Hematology Annual Meeting Abstracts110(11), (2007) (Abstract 380).
   Google Scholar
• Younes A, Pro B, Fanale M et al. Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma (HL). American Society of Hematology Annual Meeting Abstracts110(11), (2007) (Abstract 2566).
   Google Scholar
• Younes A, Wedgwood A, Mclaughlin P et al. Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a Phase II study. American Society of Hematology Annual Meeting Abstracts110(11), (2007) (Abstract 2571).
   Google Scholar
• Crump M, Coiffier B, Jacobsen ED et al. Oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed diffuse large B-cell lymphoma (DLBCL): final results of a Phase II trial. J. Clin. Oncol.25(Suppl. 18), (2007) (Abstract 18511).
   Google Scholar
• Gimsing P, Wu F, Qian X et al. Activity of the histone deacetylase (HDAC) inhibitor PXD101 in preclinical studies and in a Phase I study in patients with advanced haematological tumors. American Society of Hematology Annual Meeting Abstracts106(11), (2005) (Abstract 3337).
   Google Scholar
• Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol. Cell Biol.25(5), 1608–1619 (2005).
   PubMed Web of Science ®Google Scholar
• Tobinai K, Watanabe T, Kobayashi Y et al. Phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients (pts) with non-Hodgkin lymphoma (NHL) in Japan. J. Clin. Oncol.25(Suppl. 18), (2007) (Abstract 18521).
   Google Scholar
• Paner GP, Alkan S. Analysis of the effect of the novel histone deacetylase inhibitor, depsipeptide (FK228/FR901228) on mantle cell lymphoma. American Society of Hematology Annual Meeting Abstracts104(11), (2004) (Abstract 2499).
   Google Scholar
• Kawamata N, Chen J, Koeffler HP. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood110(7), 2667–2673 (2007).
   PubMed Web of Science ®Google Scholar
• Heider U, Kaiser M, Sterz J et al. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur. J. Haematol.76(1), 42–50 (2006).
   PubMed Web of Science ®Google Scholar
• Yazbeck VY, Georgakis GV, Li Y et al. Molecular mechanisms of the mtor inhibitor temsirolimus (CCI-779) antiproliferative effects in mantle cell lymphoma: induction of cell-cycle arrest, autophagy, and synergy with vorinostat (SAHA). American Society of Hematology Annual Meeting Abstracts108(11), (2006) (Abstract 2493).
   Google Scholar
• Kirschbaum MH, Zain JM, Popplewell L et al. A Phase 2 study of Vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent non Hodgkin lymphoma. A California Cancer Consortium Study. American Society of Hematology Annual Meeting Abstracts110(11), (2007) (Abstract 2568).
   Google Scholar
• Roychowdhury S, Baiocchi RA, Vourganti S et al. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. J. Natl Cancer Inst.96(19), 1447–1457 (2004).
   PubMed Web of Science ®Google Scholar
• Nishioka C, Ikezoe T, Yang J et al. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kB. Leuk. Res.32(2), 287–296 (2008).
   Google Scholar
• Zhao WL, Wang L, Liu YH et al. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin’s B-lymphoma cells apoptosis. Exp. Hematol.35(12), 1801–1811 (2007).
   PubMed Web of Science ®Google Scholar
• Plumas J, Jacob MC, Chaperot L et al. Tumor B cells from non-Hodgkin’s lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood91(8), 2875–2885 (1998).
   PubMed Web of Science ®Google Scholar
• Wajant H, Pfizenmaier K, Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis7(5), 449–459 (2002).
   PubMed Web of Science ®Google Scholar
• Inoue S, Macfarlane M, Harper N et al. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ.11(Suppl. s2), S193–S206 (2004).
   PubMed Web of Science ®Google Scholar
• Rephaeli A, Rabizadeh E, Aviram A et al. Derivatives of butyric acid as potential anti-neoplastic agents. Int. J. Cancer49(1), 66–72 (1991).
   PubMed Web of Science ®Google Scholar
• Siu LL, Von Hoff DD, Rephaeli A et al. Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units. Invest. New Drugs16(2), 113–119 (1998).
   PubMed Web of Science ®Google Scholar
• Rephaeli A, Entin-Meer M, Angel D et al. The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs. Invest. New Drugs24(5), 383–392 (2006).
   Google Scholar
• Loprevite M, Tiseo M, Grossi F et al. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol. Res.15(1), 39–48 (2005).
   PubMed Web of Science ®Google Scholar
• Moody TW, Nakagawa T, Kang Y et al. Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation. J. Mol. Neurosci.28(3), 231–238 (2006).
   PubMed Web of Science ®Google Scholar
• Yu XD, Wang SY, Chen GA et al. Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells. Cancer J.13(2), 105–113 (2007).
   PubMed Web of Science ®Google Scholar
• Aviram A, Rephaeli A, Shaklai M et al. Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells. J. Cancer Res. Clin. Oncol.123(5), 267–271 (1997).
   PubMed Web of Science ®Google Scholar
• Desai D, Das A, Cohen L, El-Bayoumy K, Amin S. Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. Anticancer Res.23(1A), 499–503 (2003).
   PubMed Web of Science ®Google Scholar
• Kelly WK, O’Connor OA, Krug LM et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol.23(17), 3923–3931 (2005).
   PubMed Web of Science ®Google Scholar
• Krug LM, Curley T, Schwartz L et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin. Lung Cancer7(4), 257–261 (2006).
   PubMed Web of Science ®Google Scholar
• Wozniak A, O’Shaughnessy J, Fiorica J, Grove W. Phase II Trial of CI-994 in patients (pts) with advanced nonsmall cell lung cancer (NSCLC). J. Clin. Oncol. (1999) (Abstract 1878.)
   Google Scholar
• Reid T, Valone F, Lipera W et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer45(3), 381–386 (2004).
   PubMed Web of Science ®Google Scholar
• Traynor AM, Dubey S, Eickhoff J et al. A Phase II study of vorinostat (NSC 701852 ) in patients (pts) with relapsed non-small cell lung cancer (NSCLC). J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 18044).
   Google Scholar
• Luong QT, O’Kelly J, Braunstein GD, Hershman JM, Koeffler HP. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin. Cancer Res.12(18), 5570–5577 (2006).
   Google Scholar
• Catalano MG, Fortunati N, Pugliese M et al. Valproic acid induces apoptosis and cell-cycle arrest in poorly differentiated thyroid cancer cells. J. Clin. Endocrinol. Metab.90(3), 1383–1389 (2005).
   PubMed Web of Science ®Google Scholar
• Kitazono M, Robey R, Zhan Z et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J. Clin. Endocrinol. Metab.86(7), 3430–3435 (2001).
   PubMed Web of Science ®Google Scholar
• Greenberg VL, Williams JM, Cogswell JP, Mendenhall M, Zimmer SG. Histone deacetylase inhibitors promote apoptosis and differential cell-cycle arrest in anaplastic thyroid cancer cells. Thyroid11(4), 315–325 (2001).
   Google Scholar
• Su YB, Tuttle RM, Fury M et al. A Phase II study of single agent depsipeptide (DEP) in patients (pts) with radioactive iodine (RAI)-refractory, metastatic, thyroid carcinoma: preliminary toxicity and efficacy experience. J. Clin. Oncol.24(Suppl. 18), (2006) (Abstract 5554).
   Google Scholar
• Butler LM, Agus DB, Scher HI et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res.60(18), 5165–5170 (2000).
   PubMed Web of Science ®Google Scholar
• Shabbeer S, Kortenhorst MS, Kachhap S et al. Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate67(10), 1099–1110 (2007).
   PubMed Web of Science ®Google Scholar
• Park WH, Jung CW, Park JO et al. Trichostatin inhibits the growth of ACHN renal cell carcinoma cells via cell-cycle arrest in association with p27, or apoptosis. Int. J. Oncol.22(5), 1129–1134 (2003).
   Google Scholar
• Wang X-F, Qian DZ, Ren M et al. Epigenetic modulation of retinoic acid receptor b2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin. Cancer Res.11(9), 3535–3542 (2005).
   PubMed Web of Science ®Google Scholar
• Stadler WM, Margolin K, Ferber S, Mcculloch W, Thompson JA. A Phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer5(1), 57–60 (2006).
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Flaherty L, Fiorica J, Grove W. Phase II trial of CI-994 in patients (pts) with metastatic renal cell carcinoma (RCC). J. Clin. Oncol. (1999) (Abstract 1346).
   Google Scholar
• Rundall BK, Denlinger CE, Jones DR. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. Surgery138(2), 360–367 (2005).
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Parise RA, Ramananthan RK et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin. Cancer Res.13(12), 3605–3610 (2007).
   PubMed Web of Science ®Google Scholar
• Richards DA, Boehm KA, Waterhouse DM et al. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a Phase II randomized, double-blind, placebo-controlled, multicenter study. Ann. Oncol.17(7), 1096–1102 (2006).
   PubMed Web of Science ®Google Scholar
• Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res.61(4), 1477–1485 (2001).
   PubMed Web of Science ®Google Scholar
• Verheul HM, Qian DZ, Carducci MA, Pili R. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer Chemother. Pharmacol.60(3), 329–339 (2007).
   PubMed Web of Science ®Google Scholar
• Marrocco DL, Tilley WD, Bianco-Miotto T et al. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol. Cancer Ther.6(1), 51–60 (2007).
   PubMed Web of Science ®Google Scholar
• Pili R, Rudek M, Altiok S et al. Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor MS-275 in combination with 13-cis retinoic acid in patients with advanced solid tumors. J. Clin. Oncol.24(18 Suppl.) (2006) (Abstract 3055).
   Google Scholar
• Munster P, Marchion D, Bicaku E et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J. Clin. Oncol.25(15), 1979–1985 (2007).
   PubMed Web of Science ®Google Scholar
• Rho JH, Kang DY, Park KJ et al. Doxorubicin induces apoptosis with profile of large-scale DNA fragmentation and without DNA ladder in anaplastic thyroid carcinoma cells via histone hyperacetylation. Int. J. Oncol.27(2), 465–471 (2005).
   Google Scholar
• Catalano MG, Fortunati N, Pugliese M et al. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J. Endocrinol.191(2), 465–472 (2006).
   PubMed Web of Science ®Google Scholar
• Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr. Relat. Cancer14(3), 839–845 (2007).
   PubMed Web of Science ®Google Scholar
• Imanishi R, Ohtsuru A, Iwamatsu M et al. A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy. J. Clin. Endocrinol. Metab.87(10), 4821–4824 (2002).
   Google Scholar
• Piekarz RL, Sackett DL, Bates SE. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J.13(1), 30–39 (2007).
   PubMedGoogle Scholar
• Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin. Investig. Drugs16(5), 659–678 (2007).
   PubMed Web of Science ®Google Scholar
• Page JG, Rodman LE, Heath JE, Tomaszewski JE, Smith AC. Effect of infusion rate on the toxicity of depsipeptide (NCS-63–176) in Beagle dogs. Proc. Am. Assoc. Cancer Res.36, 368 (1995) (Abstract 2193).
   Google Scholar
• Page JG, Rodman LE, Heath JE, Thomaszewski JE, Smith AC. Comparison of toxicity of depsipeptide (NSC-630176) in dogs and rats. Proc. Am. Assoc. Cancer Res.37, 374 (1996) (Abstract 2549).
   Google Scholar
• Piekarz RL, Frye AR, Wright JJ et al. Cardiac studies in patients treated with depsipeptide, FK228, in a Phase II trial for T-cell lymphoma. Clin. Cancer Res.12(12), 3762–3773 (2006).
   PubMed Web of Science ®Google Scholar
• Sandor V, Bakke S, Robey RW et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res.8(3), 718–728 (2002).
   PubMed Web of Science ®Google Scholar
• Marshall JL, Rizvi N, Kauh J et al. A Phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol.2(6), 325–332 (2002).
   PubMedGoogle Scholar
• Whittaker S, Mcculloch W, Robak T, Baran E, Prentice A; ALL Investigators. International multicenter Phase II study of the HDAC inhibitor (HDACi) depsipeptide (FK228) in cutaneous T-cell lymphoma (CTCL): Interim report. J. Clin. Oncol.24(Suppl. 18), (2006) (Abstract 3063).
   Google Scholar
• Parker C, Molife R, Karavasilis V et al. Romidepsin (FK228), a histone deacetylase inhibitor: final results of a Phase II study in metastatic hormone refractory prostate cancer (HRPC). J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 15507).
   Google Scholar
• Niesvizky R, Ely S, Diliberto M et al. Multicenter Phase II trial of the histone deacetylase inhibitor depsipeptide (FK228) for the treatment of relapsed or refractory multiple myeloma (MM). American Society of Hematology Annual Meeting Abstracts106(11), (2005) (Abstract 2574).
   Google Scholar
• Shah MH, Binkley P, Chan K et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res.12(13), 3997–4003 (2006).
   PubMed Web of Science ®Google Scholar
• Bates SE, Rosing DR, Fojo T, Piekarz RL. Challenges of evaluating the cardiac effects of anticancer agents. Clin. Cancer Res.12(13), 3871–3874 (2006).
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, de Bono J, Deangelo DJ et al. Cardiac monitoring in Phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies. J. Clin. Oncol.23(Suppl. 16), 2005) (Abstract 3131).
   Google Scholar
• Fischer T, Patnaik A, Bhalla K et al. Results of cardiac monitoring during Phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies. J. Clin. Oncol.23(Suppl. 16), (2005) (Abstract 3106).
   Google Scholar
• Prince HM, George D, Patnaik A et al. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin’s lymphoma. J. Clin. Oncol.25(Suppl. 18), (2007) (Abstract 3500).
   PubMed Web of Science ®Google Scholar
• Zhang L, Lebwohl D, Masson E et al. Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat). J. Clin. Oncol.26(2), 332–333 (2008).
   PubMed Web of Science ®Google Scholar
• Kelly WK, Richon VM, O’Connor O et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res.9(10 Pt 1), 3578–3588 (2003).
   PubMed Web of Science ®Google Scholar
• Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J. Clin. Oncol.25(22), 3362–3371 (2007).
   PubMed Web of Science ®Google Scholar
• Prince HM, George DJ, Johnstone R et al. LBH589, a novel histone deacetylase inhibitor (HDACi), treatment of patients with cutaneous T-cell lymphoma (CTCL). Changes in skin gene expression profiles related to clinical response following therapy. J. Clin. Oncol.24(18 Suppl.), (2006) (Abstract 7501).
   Google Scholar
• Gojo I, Gore SD, Jiemjit A et al. Phase I study of histone deacetylase inhibitor (HDI) MS-275 in adults with refractory or relapsed hematologic malignancies. Blood102(11), (2006) (Abstract 1408).
   Google Scholar
• Gilbert J, Baker SD, Bowling MK et al. A Phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res.7(8), 2292–2300 (2001).
   PubMed Web of Science ®Google Scholar
• Carducci MA, Gilbert J, Bowling MK et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res.7(10), 3047–3055 (2001).
   PubMed Web of Science ®Google Scholar
• Phuphanich S, Baker SD, Grossman SA et al. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro-oncol.7(2), 177–182 (2005).
   PubMed Web of Science ®Google Scholar
• Chang SM, Kuhn JG, Robins HI et al. Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J. Clin. Oncol.17(3), 984–990 (1999).
   PubMed Web of Science ®Google Scholar
• Chang SM, Kuhn JG, Ian Robins H et al. A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report. Invest. New Drugs21(4), 429–433 (2003).
   Google Scholar
• Blumenschein G, Lu C, Kies M et al. Phase II clinical trial of suberoylanilide hydroxamic acid (SAHA) in patients (pts) with recurrent and/or metastatic head and neck cancer(SCCHN). J. Clin. Oncol.22(14 Suppl.), (2004) (Abstract 5578).
   Google Scholar
• Galanis E, Jaeckle KA, Maurer MJ et al. N047B: NCCTG Phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM). J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 2004).
   Google Scholar
• Whitehead RP, McCoy S, Wollner IS et al. Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: a Southwest Oncology Group study. J. Clin. Oncol.24(18 Suppl.), (2006) (Abstract 3598).
   Google Scholar
• Fouladi M, Furman WL, Chin T et al. Phase I Study of Depsipeptide in pediatric patients with refractory solid tumors: a Children’s Oncology Group Report. J. Clin. Oncol.24(22), 3678–3685 (2006).
   PubMed Web of Science ®Google Scholar
• Haigentz M Jr, Kim M, Sarta C et al. Clinical and translational studies of depsipeptide (romidepsin), a histone deacetylase (HDAC) inhibitor, in patients with squamous cell carcinoma of the head and neck (SCCHN): New York Cancer Consortium Trial P6335. J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 6065).
   Google Scholar
• Rowinsky EK, Pacey S, Patnaik A et al. A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with advanced solid tumours. J. Clin. Oncol.22(14 Suppl.), (2004) (Abstract 3022).
   Google Scholar
• Beck J, Fischer T, Rowinsky E et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589: a novel histone deacetylase inhibitor.J. Clin. Oncol.22(14 Suppl.), (2004) (Abstract 3025).
   Google Scholar
• Gore L, Holden SN, Basche M et al. Updated results from a Phase I trial of histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumours. J. Clin. Oncol.22(14 Suppl.), (2004) (Abstract 3026).
   Google Scholar
• Hauschild A, Trefzer U, Garbe C et al. A Phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. J. Clin. Oncol.24(Suppl. 18), (2006) (Abstract 8044).
   Google Scholar
• Donovan EA, Sparreboom A, Figg W et al. Phase I trial of the oral histone deacetylase inhibitor MS-275 administered with food. J. Clin. Oncol.24(18 Suppl.), (2006) (Abstract 13036).
   Google Scholar
• Prakash S, Foster BJ, Meyer M et al. Chronic oral administration of CI-994: a Phase 1 study. Invest. New Drugs19(1), 1–11 (2001).
   PubMed Web of Science ®Google Scholar
• Zalupski M, O’shaughnessy J, Vukelja S et al. Phase II Trial of CI-994 in patients (PTS) with advanced pancreatic cancer (APC). Proc. Am. Soc. Clin. Oncol.19, 285a (2000) (Abstract 1115).
   Google Scholar
• Conley BA, Egorin MJ, Tait N et al. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin. Cancer Res.4(3), 629–634 (1998).
   PubMed Web of Science ®Google Scholar
• Edelman MJ, Bauer K, Khanwani S et al. Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug. Cancer. Chemother. Pharmacol.51(5), 439–444 (2003).
   PubMed Web of Science ®Google Scholar
• Patnaik A, Rowinsky EK, Villalona MA et al. A Phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res.8(7), 2142–2148 (2002).
   PubMed Web of Science ®Google Scholar
• Carducci M, Siu LL, Sullivan R et al. Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors. J. Clin. Oncol.24(18 Suppl.), (2006) (Abstract 3007).
   Google Scholar
• Gelmon K, Tolcher A, Carducci M et al. Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors. J. Clin. Oncol.23(16 Suppl.), (2005) (Abstract 3147).
   Google Scholar
• Steele N, Vidal L, Plumb J et al. A Phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours. J. Clin. Oncol.23(16 Suppl.), (2005) (Abstract 3035).
   Google Scholar
• Fakih MG, Pendyala L, Smith P et al. A Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC). J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 4088).
   Google Scholar
• Schelman WR, Kolesar J, Schell K et al. A Phase I study of vorinostat in combination with bortezomib in refractory solid tumors. J. Clin. Oncol.25(Suppl. 18), (2007) (Abstract 3573).
   Google Scholar
• Nemunaitis JJ, Orr D, Eager R et al. Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J.9(1), 58–66 (2003).
   PubMed Web of Science ®Google Scholar
• Undevia SD, Kindler HL, Janisch L et al. A Phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann. Oncol.15(11), 1705–1711 (2004).
   PubMed Web of Science ®Google Scholar
• Pauer LR, Olivares J, Cunningham C et al. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest.22(6), 886–896 (2004).
   PubMed Web of Science ®Google Scholar
• Reid T, Weeks A, Vakil M et al. Dose escalation study of pivanex (a histone deacetylase inhibitor) in combination with docetaxel for advanced non-small cell lung cancer. J. Clin. Oncol.22(14 Suppl.), (2004) (Abstract 7279).
   Google Scholar
• Sung MW, Waxman S. Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. Anticancer Res.27(2), 995–1001 (2007).
   Google Scholar